Tiragolumab (Anti-TIGIT) in SCLC: Skyscraper-02, a Towering Inferno
Danielle Brazel,1 Sai-Hong Ignatius Ou,1,2 Misako Nagasaka1– 3 1Department of Medicine, University of California Irvine School of Medicine, Orange, CA, USA; 2Chao Family Comprehensive Cancer Center, Orange, CA, USA; 3St. Marianna University School of Medicine, Kawasaki, JapanCorrespondence: Misako N...
Main Authors: | Brazel D, Ou SI, Nagasaka M |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2023-01-01
|
Series: | Lung Cancer: Targets and Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/tiragolumab-anti-tigit-in-sclc-skyscraper-02-a-towering-inferno-peer-reviewed-fulltext-article-LCTT |
Similar Items
-
Combining TIGIT blockade with IL‐15 stimulation is a promising immunotherapy strategy for lung adenocarcinoma
by: Baohong Luo, et al.
Published: (2024-01-01) -
Research Progress of Immune Checkpoint TIGIT in Lung Cancer Immunotherapy
by: Jieqiong WU, et al.
Published: (2022-11-01) -
ImmunoPET imaging of TIGIT in the glioma microenvironment
by: Sarah R. Vincze, et al.
Published: (2024-03-01) -
Targeting the TIGIT-PVR immune checkpoint axis as novel therapeutic option in breast cancer
by: Hauke Stamm, et al.
Published: (2019-12-01) -
TIGIT/CD226 Axis Regulates Anti-Tumor Immunity
by: Jinah Yeo, et al.
Published: (2021-02-01)